Search clinical trials for: Camrelizumab Fluzoparib

Total 486 results

Quan Wang

Completed

The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

Stomach Neoplasms

China
Fujian Medical University Union Hospital

Not yet recruiting

Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

Chemotherapy | Radiation Therapy

China
Fujian Medical University

Not yet recruiting

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Locally Advanced Gastric Cancer

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer

TNBC - Triple-Negative Breast Cancer

China
RenJi Hospital

Not yet recruiting

Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy (sPLENTY-pc)

Pediatric Cancer | Liver Cancer | Hepatoblastoma | Pediatric Solid Tumor | Transitional Cell Tumor

China
Henan Cancer Hospital

Recruiting

Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin

Squamous Cell Carcinoma of the Skin

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Withdrawn

Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer

Resectable Biliary Tract Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Breast Cancer

China
Fudan University

Active, not recruiting

Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

Neoadjuvant Therapy | High-risk Prostate Cancer

China
Jinling Hospital, China
Jiangsu Synthgene Biotechnology Co.Ltd.

Recruiting

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

Pancreatic Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Breast Cancer | Triple-Negative Breast Cancer

China
Women's Hospital School Of Medicine Zhejiang University

Recruiting

Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy

Gestational Trophoblastic Neoplasia

China
Zhejiang Cancer Hospital

Not yet recruiting

Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Second Line Treatment of Gastric Cancer
Peking University

Unknown

Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

China
Chinese PLA General Hospital

Recruiting

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | PDAC - Pancreatic Ductal Adenocarcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Breast Cancer | Triple Negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Drug-drug Interaction Trial of Rifampicin Pharmacokinetics Effect on Fluzoparib

Healthy Male Subjects

China
Zhejiang Cancer Hospital

Unknown

A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)

Colorectal Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Zhejiang Cancer Hospital

Not yet recruiting

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

Stage IV Esophagus Squamous Cell Carcinoma

China
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

Locally Advanced Non-Small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Gastric Cancer

China
First Affiliated Hospital of Zhejiang University

Not yet recruiting

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

Advanced Biliary Tract Carcinoma

China
Sun Yat-sen University

Recruiting

Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma

PDAC - Pancreatic Ductal Adenocarcinoma

China
The Central Hospital of Lishui City

Not yet recruiting

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

Hepatocellular Carcinoma
Lei Li

Completed

Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy

Chemotherapy | Recurrent Cervical Carcinoma | Immunotherapy | Anti-PD-1 Antibody | Persistent Advanced Cervical Carcinoma

China
China Medical University, China

Unknown

Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer

Advanced Gastric Cancer

China
Fudan University

Recruiting

First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients

Breast Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma | Bevacizumab | Anti-PD1/PDL1 Antibody

China
Peking Union Medical College Hospital

Recruiting

A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）

Small Cell Lung Carcinoma

China
The Affiliated Hospital of Qingdao University

Completed

Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection

Healthy Volunteers

China
Wuhan Union Hospital, China
Jiangsu HengRui Medicine Co., Ltd.; CSPC ZhongQi Pharmaceutical Technology...

Not yet recruiting

Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy

Breast Cancer

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma

Classical Hodgkin Lymphoma

China
Fudan University
Huazhong University of Science and Technology; LinkDoc Technology (Beijing)...

Not yet recruiting

Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC)

Unresectable Hepatocellular Carcinoma
University of Minnesota

Completed

Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia

Disorders of Sex Development | Urogenital Abnormalities | Congenital Adrenal Hyperplasia | Genetic Diseases, Inborn | Hyperplasia | Adrenocortical Hyperfunction | Congenital Disorders | Hydrocortisone | Adrenal Hyperplasia | Steroid Metabolic Diseases, Inborn | Adrenal Gland Disease

United States
Henan Cancer Hospital

Unknown

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Triple-negative Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Non-Small Cell Lung Cancer With HER2- Mutations

China
Henan Cancer Hospital
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Esophageal Carcinoma | Lung Cancer, Nonsmall Cell

China
Wei Jiang
Wuzhou Red Cross Hospital; Guangxi Nanxishan Hospital; Laibin People's Hospital; Lingshan people's Hospital

Recruiting

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Second Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma
Nanfang Hospital of Southern Medical University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients (PANORAMA)

Chemotherapy | Immunotherapy

China
Merck Sharp & Dohme LLC

Completed

A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)

HIV Infections
Fudan University

Recruiting

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer

Recurrent Ovarian Cancer

China
Sun Yat-sen University

Recruiting

Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hutchmed

Recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma | Immunotherapy | Preoperative

China

3

Subscribe